Pulmonary hypertension secondary to interstitial lung disease

Oksana A Shlobin; Steven D Nathan

doi:10.1586/ers.11.11

Pulmonary hypertension secondary to interstitial lung disease

Expert Rev Respir Med. 2011 Apr;5(2):179-89. doi: 10.1586/ers.11.11.

Authors

Oksana A Shlobin¹, Steven D Nathan

Affiliation

¹ Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Falls Church, VA 22042, USA.

PMID: 21510729
DOI: 10.1586/ers.11.11

Abstract

Interstitial lung diseases (ILDs) may be complicated by the development of pulmonary hypertension (PH), which is associated with worse functional impairment and a poorer prognosis. This article reviews the current state of knowledge on the prevalence, pathogenesis, diagnosis and prognosis of ILD-related PH. Whether the treatment of ILD-related PH changes clinical outcomes is currently unknown, but the current studies are summarized and the authors' perspective is offered.

Publication types

Review

MeSH terms

Antihypertensive Agents / therapeutic use
Blood Pressure
Humans
Hypertension, Pulmonary / diagnosis
Hypertension, Pulmonary / drug therapy
Hypertension, Pulmonary / epidemiology
Hypertension, Pulmonary / etiology*
Hypertension, Pulmonary / physiopathology
Lung Diseases, Interstitial / complications*
Lung Diseases, Interstitial / diagnosis
Lung Diseases, Interstitial / drug therapy
Lung Diseases, Interstitial / epidemiology
Lung Diseases, Interstitial / physiopathology
Treatment Outcome

Substances

Antihypertensive Agents